Silexion Therapeutics plans private placement for $2.5 million in net proceeds
SLXN•Silexion Therapeutics must raise $2.5 million net through a planned private placement by December 4, 2026, to retain its Nasdaq listing.
1. Nasdaq listing conditions
A Nasdaq panel granted Silexion Therapeutics conditional continued listing on November 18, 2026, requiring it to meet the $2.5 million minimum shareholders’ equity requirement. The company must maintain a closing bid of at least $1 for 10 consecutive trading days by November 24, 2026, and raise at least $5 million in a planned public offering by March 31, 2027. It must remain in compliance with all Nasdaq listing requirements through May 15, 2027; new violations during that period will trigger immediate delisting.




